Back to results
US 8,278,060 B2Granted
Use of VEGF-D in the diagnosis of lymphangioleiomyomatosis (LAM) disease
AssigneeChildren's Hospital Medical Center University of Cincinnati
InventorsFrancis X. McCormack, Lisa R. Young
Life of this patent
Estimating the term…
Abstract
Described herein are methods of diagnosing lymphangioleiomyomatosis (LAM) that permits differentiating LAM from another lung disorder. Methods of treatment are also provided.
Claims27
A method of treating lymphangioleiomyomatosis (LAM) in a human subject comprising
- (a) diagnosing a subject as having LAM by a method that comprises measuring VEGF-D concentration in a biological sample from the subject, wherein an elevated VEGF-D concentration in the sample compared to a predetermined criterion is indicative of LAM in the subject, wherein the predetermined criterion comprises VEGF-D measurements from a plurality of human subjects with tuberous sclerosis complex (TSC) or a cystic or chylous lung disorder that are free of LAM, wherein an elevated level of VEGF-D in the sample compared to the VEGF-D measurements from the human subjects that are free of LAM, is diagnostic of LAM;
- and
- (b) administering a standard of care therapeutic to the subject.
A method of treating lymphangioleiomyomatosis (LAM) in a human subject comprising
- (a) diagnosing a subject as having LAM by a method that comprises measuring VEGF-D concentration in a biological sample from the subject, wherein an elevated VEGF-D concentration in the sample compared to a predetermined criterion is indicative of LAM in the subject, wherein the predetermined criterion is a receiver operating characteristic curve based on data of VEGF-D measurements in subjects with LAM and subjects with TSC or a cystic or chylous lung disorder that are free of LAM;
- and
- (b) administering a standard of care therapeutic to the subject.
A method of treating lymphangioleiomyomatosis (LAM) in a human subject comprising
- (a) diagnosing a subject as having LAM by a method that comprises measuring VEGF-D concentration in a biological sample from the subject, wherein an elevated VEGF-D concentration in the sample compared to a predetermined criterion is indicative of LAM in the subject, wherein the predetermined criterion is a cutoff value of VEGF-D concentration, wherein the cutoff value is determined, based on previous measurements to discriminate LAM with a sensitivity and specificity calculated from measurements of VEGF-D in human subjects with LAM and human subjects with TSC or a cystic or chylous lung disorder that are free of LAM;
- and
- (b) administering a standard of care therapeutic to the subject.
Dependencies are inferred from the claim text.